Cargando…
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282202/ https://www.ncbi.nlm.nih.gov/pubmed/32517786 http://dx.doi.org/10.1186/s42358-020-00134-8 |
_version_ | 1783544083680067584 |
---|---|
author | dos Reis Neto, Edgard Torres Kakehasi, Adriana Maria de Medeiros Pinheiro, Marcelo Ferreira, Gilda Aparecida Marques, Cláudia Diniz Lopes da Mota, Licia Maria Henrique dos Santos Paiva, Eduardo Pileggi, Gecilmara Cristina Salviato Sato, Emília Inoue Reis, Ana Paula Monteiro Gomides Xavier, Ricardo Machado Provenza, José Roberto |
author_facet | dos Reis Neto, Edgard Torres Kakehasi, Adriana Maria de Medeiros Pinheiro, Marcelo Ferreira, Gilda Aparecida Marques, Cláudia Diniz Lopes da Mota, Licia Maria Henrique dos Santos Paiva, Eduardo Pileggi, Gecilmara Cristina Salviato Sato, Emília Inoue Reis, Ana Paula Monteiro Gomides Xavier, Ricardo Machado Provenza, José Roberto |
author_sort | dos Reis Neto, Edgard Torres |
collection | PubMed |
description | Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs. |
format | Online Article Text |
id | pubmed-7282202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72822022020-06-09 Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases dos Reis Neto, Edgard Torres Kakehasi, Adriana Maria de Medeiros Pinheiro, Marcelo Ferreira, Gilda Aparecida Marques, Cláudia Diniz Lopes da Mota, Licia Maria Henrique dos Santos Paiva, Eduardo Pileggi, Gecilmara Cristina Salviato Sato, Emília Inoue Reis, Ana Paula Monteiro Gomides Xavier, Ricardo Machado Provenza, José Roberto Adv Rheumatol Position Article and Guidelines Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs. BioMed Central 2020-06-09 2020 /pmc/articles/PMC7282202/ /pubmed/32517786 http://dx.doi.org/10.1186/s42358-020-00134-8 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Position Article and Guidelines dos Reis Neto, Edgard Torres Kakehasi, Adriana Maria de Medeiros Pinheiro, Marcelo Ferreira, Gilda Aparecida Marques, Cláudia Diniz Lopes da Mota, Licia Maria Henrique dos Santos Paiva, Eduardo Pileggi, Gecilmara Cristina Salviato Sato, Emília Inoue Reis, Ana Paula Monteiro Gomides Xavier, Ricardo Machado Provenza, José Roberto Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases |
title | Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases |
title_full | Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases |
title_fullStr | Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases |
title_full_unstemmed | Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases |
title_short | Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases |
title_sort | revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases |
topic | Position Article and Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282202/ https://www.ncbi.nlm.nih.gov/pubmed/32517786 http://dx.doi.org/10.1186/s42358-020-00134-8 |
work_keys_str_mv | AT dosreisnetoedgardtorres revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT kakehasiadrianamaria revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT demedeirospinheiromarcelo revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT ferreiragildaaparecida revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT marquesclaudiadinizlopes revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT damotaliciamariahenrique revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT dossantospaivaeduardo revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT pileggigecilmaracristinasalviato revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT satoemiliainoue revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT reisanapaulamonteirogomides revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT xavierricardomachado revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases AT provenzajoseroberto revisitinghydroxychloroquineandchloroquineforpatientswithchronicimmunitymediatedinflammatoryrheumaticdiseases |